Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma

Despite markedly improved treatment options for metastatic melanoma, resistance to targeted therapies such as BRAF inhibitors (BRAFi) or BRAFi plus MEK inhibitors (MEKi) remains a major problem. Our aim was to characterize progression on BRAFi therapy and outcome of subsequent treatment. One hundred...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassel, Jessica C., Buder‐Bakhaya, Kristina, Bender, Carolin, Zimmer, Lisa, Weide, Benjamin, Loquai, Carmen, Ugurel, Selma, Slynko, Alla, Gutzmer, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773979/
https://www.ncbi.nlm.nih.gov/pubmed/29266761
http://dx.doi.org/10.1002/cam4.1267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773979/
https://www.ncbi.nlm.nih.gov/pubmed/29266761
http://dx.doi.org/10.1002/cam4.1267

Ejemplares similares